Addus HomeCare Corporation (ADUS) vs BioCryst Pharmaceuticals, Inc. (BCRX)

A side-by-side comparison of Addus HomeCare Corporation and BioCryst Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ADUS vs BCRX

growth of $100 · dividends reinvested · last 10y
ADUS +316.7% (+15.3%/yr)BCRX +78.8% (+6.0%/yr)ADUS compounded faster over this window
0100200300400500Start $10020182020202220242026$417$179
ADUS BCRX

ADUS vs BCRX: by the numbers

  • •ADUS is the larger company ($2.11B vs $2.06B market cap).
  • •ADUS is profitable (7.13% net margin) while BCRX runs a net loss (-40.90%).
  • •BCRX grew revenue faster over the past five years (64.07% vs 12.67% CAGR).

Metrics side by side

Valuation

MetricADUSBCRX
P/E ratio19.82N/A
Forward P/E16.03N/A
PEG ratio0.98N/A
P/S ratio1.432.19
P/B ratio1.84N/A
EV / EBITDA12.84N/A
FCF yield7.26%17.35%

Profitability

MetricADUSBCRX
Gross margin32.36%97.82%
Operating margin10.04%38.98%
Net margin7.13%-40.90%
ROE9.17%N/A
ROIC8.61%-89.73%

Growth (annualized)

MetricADUSBCRX
Revenue CAGR (5Y)12.67%64.07%
EPS CAGR (5Y)19.61%N/A
FCF CAGR (5Y)24.41%N/A
Total return CAGR (5Y)8.33%-10.02%

Frequently asked

Which has grown faster, ADUS or BCRX?
Over the past five years, BCRX grew revenue faster — ADUS at a 12.67% CAGR versus BCRX at 64.07%.
Is ADUS or BCRX more profitable?
ADUS runs the higher net margin — ADUS at 7.13% versus BCRX at -40.90%.
How have ADUS and BCRX total returns compared?
Over the past 10 years, ADUS delivered 15.62% and BCRX delivered 5.82% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.